A 1070722
Biological Activity
Potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 0.6 nM for GSK-3α and GSK-3β). Displays high selectivity (> 50-fold) for GSK-3 over a panel of other kinases tested, including CDK family members. Decreases phosphorylation of microtubule-associated protein Tau in vitro; protects rat primary cortical neurons against β amyloid and glutamate challenge. Brain penetrant.
Compound Libraries
A 1070722 is also offered as part of the Tocriscreen Plus and Tocriscreen Kinase Inhibitor Toolbox II. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 362.31 |
| Formula | C17H13F3N4O2 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 1384424-80-9 |
| PubChem ID | 49830684 |
| InChI Key | VQPBIJGXSXEOCU-UHFFFAOYSA-N |
| Smiles | O=C(NC3=NC(C(F)(F)F)=CC=C3)NC2=CC=NC1=CC(OC)=CC=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 36.23 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 362.31. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.76 mL | 13.8 mL | 27.6 mL |
| 5 mM | 0.55 mL | 2.76 mL | 5.52 mL |
| 10 mM | 0.28 mL | 1.38 mL | 2.76 mL |
| 50 mM | 0.06 mL | 0.28 mL | 0.55 mL |
Molarity Calculator
Reconstitution Calculator
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Bakker et al (2011) A-1070722, a potent, selective, and centrally active glycogen synthase kinase-3 (GSK-3) inhibitor for the treatment of psychiatric and neurodegenerative disorders. Society for Neuroscience (Abstract) 568 PMID:
If you know of a relevant reference for A 1070722, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: A1070722 glycogen synthase kinases 3 inhibits inhibitors potent selective brain penetrant neuroprotective tau phosphorylation beta b amyloid Glycogen Synthase Kinase 3
Citations for A 1070722
Citations are publications that use Tocris products.
Currently there are no citations for A 1070722. Do you know of a great paper that uses A 1070722 from Tocris? If so please let us know.
Literature in this Area
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Kinases Product Listing
A collection of over 400 products for kinase research, the listing includes inhibitors of:
- Receptor Tyrosine Kinases
- Protein Kinases A, C, D and G
- PI-3 Kinase, Akt and mTOR
- MAPK Signaling
- Receptor Serine/Threonine Kinases
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia PosterNew
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
